Tharimmune Inc (THAR)

$1.35 +0.03 (2.27%)
Market Cap 5.57M
Revenue (ttm) 0.00
Net Income (ttm) -12.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.31
Volume 23,600
Avg Vol 75,582
Day's Range N/A - N/A
Shares Out 4.22M
Stochastic %K 39%
Beta 1.17
Analysts Strong Buy
Price Target $17.00

Company Profile

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH023 which is phase 1 clinical trial used to treat multiple high value autoimmune indications; and HS1940, which targets prog...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 270 8260
Address:
1200 Route 22 East, Suite 2000, Bridgewater, United States
MarkMcLain
MarkMcLain Aug. 15 at 2:16 AM
$THAR
0 · Reply
MarkMcLain
MarkMcLain Aug. 14 at 7:53 PM
$ATCH Realistic target. Eyes on $THAR reversal
0 · Reply
MarkMcLain
MarkMcLain Aug. 14 at 3:55 PM
$THAR where is the volume? Late start?
0 · Reply
tusambolo
tusambolo Aug. 13 at 6:03 PM
$THAR anchored down by dilution, positive side is insiders holding a nice chunk
0 · Reply
Dani_G_German
Dani_G_German Aug. 13 at 5:51 PM
$THAR I’m in
0 · Reply
Stock__Hunter
Stock__Hunter Aug. 13 at 4:37 PM
$THAR not going anywhere
0 · Reply
natureman67
natureman67 Aug. 13 at 3:06 PM
$THAR shake out. Buy the dip
0 · Reply
all1nn
all1nn Aug. 13 at 3:03 PM
$THAR nasty drop
1 · Reply
BioTerror
BioTerror Aug. 13 at 3:02 PM
$THAR good news out this morning! Small float can move quick 🚀
0 · Reply
Mimarcano
Mimarcano Aug. 13 at 2:53 PM
$THAR 👀👀
0 · Reply
Latest News on THAR
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Aug 13, 2025, 8:01 AM EDT - 3 days ago

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Aug 5, 2025, 8:00 AM EDT - 11 days ago

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

Aug 4, 2025, 8:00 AM EDT - 12 days ago

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Jul 23, 2025, 10:15 PM EDT - 23 days ago

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Jun 17, 2025, 8:01 AM EDT - 2 months ago

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 6, 2025, 8:01 AM EDT - 3 months ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

May 1, 2025, 8:01 AM EDT - 3 months ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Apr 30, 2025, 8:01 AM EDT - 3 months ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Apr 28, 2025, 8:01 AM EDT - 3 months ago

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Apr 15, 2025, 9:00 AM EDT - 4 months ago

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Apr 7, 2025, 8:00 AM EDT - 4 months ago

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Mar 31, 2025, 8:00 AM EDT - 4 months ago

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Mar 24, 2025, 8:00 AM EDT - 5 months ago

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Mar 4, 2025, 7:00 AM EST - 5 months ago

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Tharimmune to Present at the Microcap Conference 2025

Jan 27, 2025, 8:30 AM EST - 7 months ago

Tharimmune to Present at the Microcap Conference 2025

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Dec 16, 2024, 8:00 AM EST - 8 months ago

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Dec 6, 2024, 4:15 PM EST - 9 months ago

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Nov 18, 2024, 8:00 AM EST - 9 months ago

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Nov 13, 2024, 8:00 AM EST - 9 months ago

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune Announces Upcoming Conference Presentations

Nov 4, 2024, 9:00 AM EST - 10 months ago

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Oct 30, 2024, 8:00 AM EDT - 10 months ago

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Oct 28, 2024, 9:00 AM EDT - 10 months ago

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Sep 30, 2024, 7:00 AM EDT - 11 months ago

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Sep 16, 2024, 7:00 AM EDT - 11 months ago

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Jul 17, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Apr 30, 2024, 8:31 AM EDT - 1 year ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Apr 23, 2024, 7:31 AM EDT - 1 year ago

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Apr 15, 2024, 8:31 AM EDT - 1 year ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

OABI

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Mar 5, 2024, 8:31 AM EST - 1 year ago

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Feb 20, 2024, 8:01 AM EST - 1 year ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Feb 5, 2024, 8:30 AM EST - 1 year ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Jan 29, 2024, 8:00 AM EST - 1 year ago

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Dec 11, 2023, 8:01 AM EST - 1 year ago

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Nov 30, 2023, 4:01 PM EST - 1 year ago

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Nov 27, 2023, 9:40 PM EST - 1 year ago

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Nov 27, 2023, 8:00 AM EST - 1 year ago

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Tharimmune Announces 1-for-25 Reverse Stock Split

Nov 17, 2023, 7:00 AM EST - 1 year ago

Tharimmune Announces 1-for-25 Reverse Stock Split

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Nov 6, 2023, 5:35 PM EST - 1 year ago

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Sep 22, 2023, 8:30 AM EDT - 2 years ago

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Sep 11, 2023, 11:51 AM EDT - 2 years ago

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Sep 8, 2023, 2:30 PM EDT - 2 years ago

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Aug 9, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

Jul 20, 2023, 8:00 AM EDT - 2 years ago

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Jul 10, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

Jul 6, 2023, 8:30 AM EDT - 2 years ago

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

May 15, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

Hillstream BioPharma Announces Closing of Public Offering of Common Stock

May 2, 2023, 4:05 PM EDT - 2 years ago

Hillstream BioPharma Announces Closing of Public Offering of Common Stock

Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences

May 2, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences

MarkMcLain
MarkMcLain Aug. 15 at 2:16 AM
$THAR
0 · Reply
MarkMcLain
MarkMcLain Aug. 14 at 7:53 PM
$ATCH Realistic target. Eyes on $THAR reversal
0 · Reply
MarkMcLain
MarkMcLain Aug. 14 at 3:55 PM
$THAR where is the volume? Late start?
0 · Reply
tusambolo
tusambolo Aug. 13 at 6:03 PM
$THAR anchored down by dilution, positive side is insiders holding a nice chunk
0 · Reply
Dani_G_German
Dani_G_German Aug. 13 at 5:51 PM
$THAR I’m in
0 · Reply
Stock__Hunter
Stock__Hunter Aug. 13 at 4:37 PM
$THAR not going anywhere
0 · Reply
natureman67
natureman67 Aug. 13 at 3:06 PM
$THAR shake out. Buy the dip
0 · Reply
all1nn
all1nn Aug. 13 at 3:03 PM
$THAR nasty drop
1 · Reply
BioTerror
BioTerror Aug. 13 at 3:02 PM
$THAR good news out this morning! Small float can move quick 🚀
0 · Reply
Mimarcano
Mimarcano Aug. 13 at 2:53 PM
$THAR 👀👀
0 · Reply
MarkMcLain
MarkMcLain Aug. 13 at 2:45 PM
$THAR Government purchases on the way? Product has MULTIPLE uses.
0 · Reply
Fish_Bone_Capone
Fish_Bone_Capone Aug. 13 at 2:33 PM
$THAR 😳💰👍The granted and allowed patents include: United States (US) Application No. 17/285,971 (Allowed) Japan (JP) Patent No. 7603583 (Granted) Mexico (MX) Patent No. 422769 (Granted) Australia (AU) Patent Application No. 2019361980 (Allowed) https://finviz.com/news/138979/tharimmune-secures-key-global-patents-for-th-104-laying-foundation-for-broader-indications-following-initial-development-as-a-national-security-medical-countermeasure-against-weaponized-fentanyl
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Aug. 13 at 2:31 PM
$WBTN 16.30 atm. Going up $THAR shorts havent covered (low float) - Float & OS:3.04M / 5.37M. Volume 1,183,797, Avg. Volume 38,67
0 · Reply
Stockttwits619
Stockttwits619 Aug. 13 at 2:08 PM
$MNTS $BNC $ADN $THAR $SONN low flt ez 7-25%
0 · Reply
Baba200TradeBot
Baba200TradeBot Aug. 13 at 2:00 PM
LowFloatReport.com - 🔥 - Top 5 Low Float High Relative Volume (Post Market Open) as of 08/13/25 - 10:00 AM $ADD - Volume: 54.8M - Prev Volume: 236K - Float: 28.15 - Rel Vol: 1252.7x - Chng%: -73.8% $MNTS - Volume: 142.3M - Prev Volume: 101K - Float: 8.44 - Rel Vol: 993.1x - Chng%: +91.0% $SPNS - Volume: 9.2M - Prev Volume: 915K - Float: 30.64 - Rel Vol: 405.1x - Chng%: +44.4% $THAR - Volume: 990K - Prev Volume: 45K - Float: 2.06 - Rel Vol: 217.1x - Chng%: +7.9% $XFOR - Volume: 53.4M - Prev Volume: 875K - Float: 7.67 - Rel Vol: 187.6x - Chng%: +16.9%
0 · Reply
Dingo2
Dingo2 Aug. 13 at 1:36 PM
$THAR hey, nice volume out of the gate! Way over daily average 5 minutes in...
0 · Reply
Baba200TradeBot
Baba200TradeBot Aug. 13 at 1:01 PM
lowfloatreport.com/ - $THAR 🔥 Today’s tape is dripping with velocity: 784 K shares have already changed hands—406× the 39 K daily norm—churning through 37 % of the tiny 2.06 M float before lunch, so liquidity can vanish in a blink and every marginal buyer ramps price faster than shorts can even locate shares 🥵. With price launching from a 1.40 open to a 1.83 pre-market high (+30 % swing) on fresh global-patent news, we’ve got the textbook low-float squeeze setup—volume > float = rocket fuel, ATR sits at just 0.14 so each incremental bid stretches ranges, and if turnover pushes past 1× float (~2.1 M) algos looking for relative-strength and momentum flags could drive either a parabolic melt-up or a face-ripping reversal 🚀📈. Manage risk, respect the tape, and remember that when volume dwarfs supply, price action writes its own rules 🧨. Full data: LowFloatReport.com
0 · Reply
_2025
_2025 Aug. 13 at 12:59 PM
$THAR @Sensore How do you do it, how do you know?
0 · Reply
SixFigureDream
SixFigureDream Aug. 13 at 12:57 PM
$THAR relative volume spike to 400.8x
0 · Reply
_2025
_2025 Aug. 13 at 12:52 PM
$THAR VERY GOOD NEWS! Technology: TH-104 is a mucoadhesive film for administering nalmefene, an opioid antagonist with a longer half-life than existing alternatives. Patent Protection: The new patents cover the method and device for administration, providing platform protection until at least 2040. Accelerated Approval Pathway: The FDA's confirmation of the 505(b)(2) pathway allows the company to rely on existing data from approved drugs, which can significantly expedite the registration and commercialization process. Primary Application: The company's initial focus is positioning TH-104 as a national security solution for military and first responders exposed to high-potency opioids. Future Applications: The company stated the patents will also support potential future uses in treating pruritus associated with chronic liver and kidney diseases.
0 · Reply
premarketmaker
premarketmaker Aug. 13 at 12:45 PM
$THAR this is why we wait! A real Let down so far, no volume, follow thru, moving to new daily low - failing to entertain us but we are okay-
0 · Reply
Baba200TradeBot
Baba200TradeBot Aug. 13 at 12:30 PM
LowFloatReport.com - 🔥 - Top 5 Low Float High Relative Volume (Premarket 2) as of 08/13/25 - 8:30 AM $MNTS - Volume: 25.4M - Prev Volume: 101K - Float: 8.44 - Rel Vol: 418.6x - Chng%: +34.2% $THAR - Volume: 610K - Prev Volume: 45K - Float: 2.06 - Rel Vol: 316.0x - Chng%: +4.3% $SPNS - Volume: 2.6M - Prev Volume: 915K - Float: 30.64 - Rel Vol: 267.8x - Chng%: +44.0% $BSLK - Volume: 28.6M - Prev Volume: 87K - Float: 1.37 - Rel Vol: 237.4x - Chng%: +78.4% $XFOR - Volume: 28.4M - Prev Volume: 875K - Float: 7.67 - Rel Vol: 235.9x - Chng%: +15.1%
0 · Reply